Clinical review report: Burosumab (Crysvita) (Kyowa Kirin limited) indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and older
The objective of this CADTH Common Drug Review is to perform a systematic review of the beneficial and harmful effects of burosumab for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
Edition: | Final |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this CADTH Common Drug Review is to perform a systematic review of the beneficial and harmful effects of burosumab for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older |
---|---|
Physical Description: | 1 PDF file (197 pages) illustrations |